ClinicalTrials.gg
WithdrawnNCT04683237Updated Sep 26, 2024

Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

A Phase 2/3 interventional study of Liraglutide Injection and Megestrol Acetate 160 MG in Atypical Endometrial Hyperplasia, Obese and Fertility Issues, sponsored by Xiaojun Chen. Withdrawn. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-09-26.

Sponsored by Xiaojun Chen · Phase 2/3, Interventional, and Treatment

How we know

Why this study was withdrawn
Based on our latest research results, we will revise the protocol and design a better study. Since no participants are enrolled till now, we withdraw this study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

To investigate the efficacy of liraglutide plus megestrol acetate in obesity patients with atypical endometrial hyperplasia (AEH)

Read the detailed description

Backgrounds: High-dose progesterone (MA/MPA) or LNG-IUS is the first-line treatment for women with atypical endometrial hyperplasia (AEH) or early endometrioid cancer who want to preserve fertility. About 70-80% of them can achieve complete response (CR) with the median time of 7-8 months. Over 10% of the patients can not achieve CR and choose operation finally. By the way, long-term treatment of progesterone has many side effects. Our previous study showed that overweight (BMI≥25kg/m2) AEH patients had a significantly increased risk of progesterone treatment failure, and the time to achieve CR is significantly prolonged. What's more, the greater the baseline weight of AEH patients, the greater the weight gains after high-dose progesterone treatment. Obese AEH patients have a lower response to high-dose progesterone. Weight management and lifestyle interventions are clearly written into 2020 uterine NCCN guidelines. We also find that metformin may improve insulin resistance in patients with AEH, and shorten time to achieve CR and increase the CR rates.

Liraglutide is a GLP-1 receptor agonist (GLP-1RA), which is one of the commonly used hypoglycemic drugs, has been approved for losing weight. And it is applicable for patients with BMI≥30 kg/m2 or ≥27 kg/m2 combined with one of the following: diabetes, hypertension, hyperlipidemia, sleep apnea. Liraglutide acts through improving insulin sensitivity, decreasing glucagon secretion , inhibiting appetite, delaying gastric emptying and improving whole-body inflammation condition.

Objective: To investigate whether liraglutide plus MA improve the efficacy of preserving fertility when compared to MA alone in obese women with AEH who want fertility conservation.

Design: A pilot prospective randomized controlled study is designed. And this study is open-label. We use SPSS (version 22.0,IBM) to design simple randomization. And participants will be randomly assigned (1:1) to receive MA alone or liraglutide plus MA. Patients in MA alone group will receive MA 160mg po qd and patients in the liraglutide plus MA group will receive liraglutide additionally with dose of 1.8mg/d or the max tolerance dose.

All enrolled patients will receive mentoring in weight management and lifestyle improvement. Hysteroscopic assessment will be performed every 12-16 weeks while other indexes will be evaluated every month, including weight, metabolic indications,inbody fat analysis, inflammation indicators and so on.

For the efficacy evaluation, CR is defined as the reversion of endometrial atypical hyperplasia to proliferative or secretory endometrium; partial response (PR) is defined as regression to simple or complex hyperplasia without atypia; no response (NR) is defined as the persistence of the disease; and progressive disease (PD) is defined as the appearance of endometrial cancer in patients. Continuous therapies will be needed in PR, NR or PD. Two months of maintenance treatment will be recommended for patients with CR, and participants will be followed up for 2 years.

Outcomes: Primary outcome is the CR rates of the two groups (MA alone VS MA+ liraglutide) . secondary outcomes include improvement of weight, insulin resistance, chronic inflammation condition, and time to achieve CR, and safety and side events during the therapy, and the recurrence rates, pregnancy rates and live birth rates in two years.

02

Conditions studied

  • Atypical Endometrial Hyperplasia
  • Obese
  • Fertility Issues
03

In context

Endometrial Hyperplasia

110 studies on the registry are indexed under Endometrial Hyperplasia; 38 are open to participants now.

Browse Endometrial Hyperplasia studies →

Lead sponsor

Xiaojun Chen is the lead sponsor of 9 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (body mass index) ≥28kg/m2
  • Consent informed and signed
  • confirmed as endometrial atypical hyperplasia
  • Have a strong desire to reproduce and ask for fertility preservation or those who insist on keeping the uterus despite no reproductive requirements
  • Have good compliance and follow-up conditions, and patients are willing to follow up in Obstetrics and Gynecology Hospital of Fudan University in time

Exclusion criteria

Exclusion Criteria:

  • Diagnosed as type 2 diabetes
  • Diabetic ketoacidosis
  • History of acute pancreatitis
  • Have a history or family history of medullary thyroid carcinoma; multiple endocrine neoplasia syndrome type 2 (MEN2)
  • Combined with severe medical disease or severely impaired liver and kidney function
  • Patients with other types of endometrial cancer or other malignant tumors of the reproductive system; patients with breast cancer or other hormone-dependent tumors that cannot be used with progesterone
  • Those who require hysterectomy or other methods other than conservative treatment with drugs
  • Deep vein thrombosis, stroke, myocardial infarction
  • Smokers (≥15 cigarettes/day)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Other
    MA alone

    enrolled patients will receive megestrol acetate 160mg po qd

    Drug: Megestrol Acetate 160 MG

  • Experimental
    MA+liraglutide

    enrolled patients will receive megestrol acetate 160mg po qd plus liraglutide (1.8mg/d or the max tolerable dosage)

    Drug: Liraglutide Injection · Drug: Megestrol Acetate 160 MG

Interventions

  • DrugLiraglutideStudies of LiraglutideLiraglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Initiate liraglutide with a dose of 0.6 mg daily for one week. After one week at 0.6 mg per day, increase the dose to 1.2 mg daily in a week, and increase the dose to 1.8 mg daily after at least one week of treatment with the 1.2 mg daily dose. If the patients can not tolerate 1.8mg per day, decrease the dose to the max tolerable dose.

    Also known as: victoza, Nuo he li

  • DrugMegestrol AcetateStudies of Megestrol AcetateMegestrol Acetate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    160mg po qd

    Also known as: Yi li zhi, Megace

06

What researchers measure

Primary outcomes

  1. Pathological complete response (CR) rates

    The 28-week CR rates will be calculated in two groups

    Time frame: From date of randomization until the date of CR, assessed up to 28 weeks.

Secondary outcomes

  1. weight lose

    weight changing in 28-week's intervention, weight will be recorded every 4 weeks.

    Time frame: From date of randomization until the date of CR, assessed up to 28 weeks

  2. changing of insulin resistance

    Glycated hemoglobin,Glucose tolerance test,Insulin release test,and C peptide release test will be performed at baseline and 28-week. During 12-16 week, fasting glucose, insulin, glycated hemoglobin and fasting C peptide will be tested once.

    Time frame: From date of randomization until the date of CR, assessed up to 28 weeks.

  3. improvement of chronic inflammation

    improvement of chronic inflammation indications in 28 weeks. In detail, indicators including TNF-α、IL-1, IL-6 and Creatine Kinase will be tested at 0,12-16th and 28th week.

    Time frame: From date of randomization until the date of CR, assessed up to 28 weeks

  4. Time of pathological complete response (CR)

    Time of histologic regression from AEH to proliferative or secretory endometrium

    Time frame: From date of randomization until the date of CR, assessed up to 2 years.

  5. safety and side effects

    Adverse events related with Liraglutide and MA. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 will be recorded, as well as incidence of adverse events.

    Time frame: From date of randomization until the date of CR, assessed up to 2 years.

  6. Relapse rates

    All enrolled patients will be followed up for 2 years. During the following-up period, if patients recur after complete regression, they will be counted and the number of recurrence will be divided by number of patients followed up, then we can get the relapse rates.Comparison will be performed between two groups.

    Time frame: up to 2 years after the treatment for each patient

  7. pregnancy outcomes

    For patients have a desire for fertility, pregnancies, births and related outcomes will be counted, and the rate of pregnancy will be counted as number of pregnancies/ number of patients trying to fertility in the following period. Comparison will be performed between two groups

    Time frame: up to 2 years after the treatment for each patient

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2021 (actual). Primary completion is estimated for Nov 2025, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2020
First posted
Dec 24, 2020
StartActual
Mar 20, 2021
Primary completionEst.
Nov 30, 2025
CompletionEst.
Nov 30, 2026
Last update
Sep 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04683237
Lead sponsor
Xiaojun Chen
Collaborators
Huashan Hospital
Responsible party
Xiaojun Chen (Principal Investigator, Fudan University) — Sponsor-investigator
First posted
Dec 24, 2020
Start date
Mar 20, 2021
Primary completion
Nov 30, 2025 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Sep 26, 2024

Study contacts

xiaojun chen
principal investigator · Obstetrics & Gynecology Hospital of Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion